Vimarsana
Biggest News Aggregation in the World

Page 2 - Safer Technologies Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Safer Technologies Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Safer Technologies Program Today - Breaking & Trending Today

UroMems Announces Results of First Patient in Smart Implant Study to Treat Stress Urinary Incontinence - Vimarsana News

UroMems Announces Results of First Patient in Smart Implant Study to Treat Stress Urinary Incontinence

/PRNewswire/ -- UroMems, a global company developing innovative, mechatronics technology to treat stress urinary incontinence (SUI), announced today that it...

FDA Roundup: March 7, 2023 - Vimarsana News

FDA Roundup: March 7, 2023

/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a Letter...

FDA Announces Total Product Life Cycle Advisory Program (TAP) Pilot | Goodwin - Vimarsana News

FDA Announces Total Product Life Cycle Advisory Program (TAP) Pilot | Goodwin

The U.S. Food and Drug Administration’s (“FDA” or “the Agency”) Center for Devices and Radiological Health (“CDRH”) recently announced the launch of its Total Product Life Cycle...

Linear Health Sciences Recognized for Leading the Way to Safer IV Treatment for Children - Vimarsana News

Linear Health Sciences Recognized for Leading the Way to Safer IV Treatment for Children

Device Intended to Reduce Risk of IV Catheter Failure and Replacement in Hospitals Recognized by Pediatrics Consortium, FDAOKLAHOMA CITY--(BUSINESS WIRE)--#IVdislodgement--Linear Health Sciences, developer of the Orchid SRV tension-activated breakaway safety release valve, has been recognized for leading the way to...

Future therapies' costs worry Medicaid programs - Vimarsana News

Future therapies' costs worry Medicaid programs

Medicare will likely pick up the bulk of the tab on both treatments (keeping in mind one approval hasn’t happened yet).